-Reuters
HTG Molecular Diagnostics Received Notice From Nasdaq That Co. Does Not Satisfy One Of Nasdaq’s Continued Listing Requirement In Nasdaq Stock Market Rule 5550(b)
On November 18, 2022, HTG Molecular Diagnostics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of the